GlaxoSmithKline share price down 2% despite shingles vaccine boosting earnings over estimates

The pharmaceutical giant saw its Q1 earnings exceed analysts’ estimates, driven by shingles drug sales forecast at over £1 billion.

GlaxoSmithKline (GSK) recorded a great start to the new year on Wednesday, with the pharmaceutical company’s Q1 earnings exceeding analysts’ estimates, driven by strong sales growth of its shingles vaccine Shingrix.

‘We have made a strong start to 2019, which is an important year of execution for GSK, with growth in sales, operating margins and earnings per share in Q1, in line with our expectations,’ GSK CEO Emma Walmsley said.

‘Strengthening our pipeline remains our number one priority and we reported positive data for several potential new medicines in HIV and Oncology during the quarter.’

Shingrix launched back in 2017, with the vaccine becoming a major provider of growth for the drug maker in the wake of largescale restructuring at the company that saw it spin off and sell several units.

‘Shingrix has delivered another fantastic performance in the quarter,’ Walmsley told journalists on a GSK results call.

In fact, the vaccine has sold so well that GSK forecasts sales to exceed £1 billion in 2019, with it bringing in £357 million in Q1, representing a 61.5% increase over the previous quarter.

Sales of the vaccine were driven primarily by the US, but strong growth was also recorded in Canada and in Germany.

GSK results: key figures

Overall, pharmaceutical sales climbed 4% over the same period last year to £4.2 billion, while vaccines rose 23% to £1.5 billion and consumer healthcare edged 1% higher to £2 billion.

Total earnings per share doubled to 16.8p a share, with net cash flow from operations at £663 million.

GSK also declared a 19p dividend for the quarter and expects to deliver an 80p pay-out to shareholders for the full-year 2019.

Further M&A activity on the horizon for GSK

GSK will look at further inorganic growth opportunities this year, but any deals it does pursue will likely be smaller in scale to those completed in the past, with a focus on businesses in immunology, genetics and new technologies, Walmsey said on a call with reporters.

The company is also interested in cell and gene therapies for its pipeline, with the drug maker looking to improve its manufacturing operations too, she added.

The statement comes amid plans to create a consumer health joint venture with rival Pfizer, with the CEO reporting that integration is going well, with the transaction scheduled for completion in the second half of the year, subject to regulatory approval.

IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.

Please see important Research Disclaimer.

European Central Bank meeting

Learn about how the ECB meeting affects interest rates and price stability ahead of the next announcement on 24 October 2019.

  • How might the next meeting affect the markets?
  • What are the key rate decisions to watch?
  • Why is the Governing Council announcement important for traders?

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
Sell
Buy
Updated
Change
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Sell
Buy
Updated
Change

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Sell
Buy
Updated
Change
-
-
-
-
-
-
-
-
-
-
-
-
China 300
-
-
-
-

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.

The Momentum Report

Get the week’s momentum report sent directly to your inbox every Monday for FREE. The Week Ahead gives you a full calendar of upcoming key events to monitor in the coming week, as well as commentary and insight from our expert analysts on the major indices to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.